The rise of Sildenafil initially drove a boom for major pharmaceutical companies, but recent changes present a uncertain picture for those considering a stake. Lower-cost competitors are eating into revenue, and persistent patent challenges add more difficulty to the landscape. While specific companies may still gain from related offerings, the bro